Search research articles
Contact Us
Filters
Showing results (231-240 of 383) with videos related to
Page
of 39
Sort By:
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
Leukemia & Lymphoma
|
October 24, 2012
Immune reconstitution after combined haploidentical and umbilical cord blood transplant
Nitin Jain, Hongtao Liu, Andrew S Artz, et al.
British Journal of Haematology
|
October 27, 2025
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies
Miles Thomas, Hannah Johnston, Emily Dworkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
Lewis R Silverman, Erin P Demakos, Bercedis L Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2007
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
Michael R Grever, David M Lucas, Gordon W Dewald, et al.
Scientific Reports
|
May 24, 2020
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer
Maria Gagliardi, Mary Kathryn Pitner, Jihyun Park, et al.
JAMA Network Open
|
December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia
Aaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Blood Advances
|
March 29, 2022
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
Zachary D Epstein-Peterson, Andriy Derkach, Susan Geyer, et al.
Blood
|
August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Page
of 39
Search research articles
Search
Showing results (231-240 of 383) with videos related to
Sort By:
Page
of 39
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
Leukemia & Lymphoma
|
October 24, 2012
Immune reconstitution after combined haploidentical and umbilical cord blood transplant
Nitin Jain, Hongtao Liu, Andrew S Artz, et al.
British Journal of Haematology
|
October 27, 2025
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies
Miles Thomas, Hannah Johnston, Emily Dworkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
Lewis R Silverman, Erin P Demakos, Bercedis L Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2007
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
Michael R Grever, David M Lucas, Gordon W Dewald, et al.
Scientific Reports
|
May 24, 2020
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer
Maria Gagliardi, Mary Kathryn Pitner, Jihyun Park, et al.
JAMA Network Open
|
December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia
Aaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Blood Advances
|
March 29, 2022
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
Zachary D Epstein-Peterson, Andriy Derkach, Susan Geyer, et al.
Blood
|
August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Page
of 39